Business Wire

HAUSFELD-&-CO-LLP

22.2.2021 09:02:10 CET | Business Wire | Pressemeddelelse

Del
Det britiske konkurrenceankenævn, Competition Appeal Tribunal, skal behandle to begæringer om kollektive søgsmål, som omhandler valutahandelskarteller

Fra 12. til 16. juli 2021 vil Competition Appeal Tribunal (CAT) tage stilling til, hvorvidt det skal godkende en begæring om kollektivt søgsmål/gruppesøgsmål (FX Claim UK ) indbragt af Phillip Evans, repræsentant for gruppen og tidligere formand for undersøgelseskomitéen ved den britiske Competition and Markets Authority. Søgsmålet er rettet mod enheder, der indgår i følgende bankkoncerner: Barclays, Citibank, The Royal Bank of Scotland/NatWest, JPMorgan, UBS og MUFG Bank.

Hver af bankerne har indrømmet overtrædelser af EU's konkurrencelovgivning i forbindelse med spothandel med valuta. Phillip Evans’ foreslåede krav søger kompensation fra bankerne på vegne af foreslåede grupper af personer, som hævdes at have lidt tab som følge af bankernes deltagelse i de pågældende overtrædelser.

CAT har udstedt en bekendtgørelse vedrørende dette retsmøde, som kan findes her .

Phillip Evans har engageret Hausfeld & Co LLP, et førende advokatfirma inden for tvister og konflikter, til at føre sagen. Hausfeld & Co LLP’s amerikanske søsterselskab, Hausfeld LLP, er et af de førende advokatfirmaerne i et lignende kollektivt søgsmål i USA, der inddrev mere end 2,3 mia. USD til personer, som var blevet berørt af overtrædelser mht. valutahandel i USA.

Phillip Evans' begæring anmoder CAT om at godkende kravet som kvalificeret til at fortsætte som kollektivt søgsmål på vegne af berettigede enheder og enkeltpersoner samt at godkende, at Phillip Evans agerer som repræsentant for gruppen.

CAT behandler Phillip Evans' begæring samtidigt med en anden begæring om kollektivt søgsmål relateret til valutahandelskarteller, der er fremsat af Michael O’Higgins FX Class Representative Limited. Det betyder, at CAT skal afgøre, hvilken af repræsentanterne der er bedst egnet til at handle som repræsentant for gruppen. Dette er første gang, at CAT er blevet bedt om at afklare en tvist af denne type i relation til kollektive søgsmål.

Enhver person med interesse i de to begæringer (herunder foreslåede medlemmer af gruppen) kan gøre indsigelse mod en af eller begge begæringerne eller bemyndigelsen af en af eller begge foreslåede repræsentanter ved at kontakte CAT og angive deres grunde til at gøre indsigelse senest kl. 16.00 den 4. maj 2021. Disse personer kan også anmode om tilladelse til at fremsætte skriftlige og/eller mundtlige bemærkninger under retsmødet i juli ved at sende en ansøgning herom, understøttet med begrundelser, til domstolen senest kl. 16.00 den 4. maj 2021.

Phillip Evans udtaler: "Det er i gruppens medlemmers interesse, at spørgsmål om certificering og valg af repræsentant afgøres så hurtigt som muligt. Det glæder mig, at domstolen har besluttet at afholde retsmødet om certificeringen i juli 2021."

Med forbehold for eventuelle ændringer som følge af Covid-19-pandemien vil retsmødet finde sted i Competition Appeal Tribunal, Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP. For oplysninger om, hvordan du deltager i domstolens behandling af de to begæringer ved at aflevere skriftlige bemærkninger eller for at ansøge om at blive hørt ved retsmødet i juli, skal du gå ind på www.fxclaimuk.com og læse CATs bekendtgørelse her .

Slut

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye